Multiplex technologies for the assessment of minimal residual disease and low‐level mutation detection in leukaemia: mass spectrometry versus next‐generation sequencing-Reference-Cited by-同舟云学术

Multiplex technologies for the assessment of minimal residual disease and low‐level mutation detection in leukaemia: mass spectrometry versus next‐generation sequencing

Published:2021-06-14 Issue:1 Volume:196 Page:19-30
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Shanmuganathan Naranie¹²³⁴⁵^ORCID,Branford Susan²³⁴⁵

Affiliation:

1. Department of Haematology Royal Adelaide Hospital and SA Pathology Adelaide South AustraliaAustralia

2. Department of Genetics and Molecular Pathology and Centre for Cancer Biology SA Pathology Adelaide South AustraliaAustralia

3. Precision Medicine Theme South Australian Health and Medical Research Institute (SAHMRI) Adelaide South AustraliaAustralia

4. School of Pharmacy and Medical Science University of South Australia Adelaide South AustraliaAustralia

5. School of Medicine University of Adelaide Adelaide South Australia Australia

Funder

National Health and Medical Research Council

Royal Adelaide Hospital

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17623

Reference87 articles.

1. Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

2. Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

3. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

4. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

5. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials;Frontiers in Oncology;2023-02-22

2. A special issue on modern genomics in diagnostic haematology;British Journal of Haematology;2021-08-31